Summit Therapeutics could not raise $500 million in the public markets. AstraZeneca stepped in with $2 billion at a premium price. That changed everything. The deal gives AstraZeneca about 10% of Summit and a shot at its PD-1/VEGF bispecific. It also exposes a sharp divide. Strategic buyers like AstraZeneca are paying up. Public biotech investors are not. The question is simple. Does AstraZeneca see value others missed, or is it just taking a wild shot that public funds already gave up on?
Biotech looks strong on paper. The XBI is up 27% this year. It beats the S&P 500, NASDAQ, and XLV. But that number is misleading. Eric Schmidt said on Biotech Hangout that the index is held up by a few names—Moderna, Iovance, and Summit Therapeutics. These are under-owned and heavily shorted. The stocks that specialist funds actually hold have been “getting hammered.” The index hit $169 in late August, then dropped 9%. Q3 ended flat. Schmidt calls it “massive dispersion.” The split has only grown since Moderna’s August vaccine news.
AstraZeneca’s investment was made through the purchase of about 108,955 newly issued convertible preferred shares, each convertible at a 1:1,000 ratio into common stock, providing Summit with significant capital to accelerate ivonescimab development.
Strategic capital and public market reality
The week of October 2, 2026, made the split obvious. AstraZeneca’s Summit deal and the Regeneron–Sanofi antibody partnership grabbed headlines. But under the radar, three China licensing deals closed. Mirum Pharmaceuticals got its third FOP approval. AbbVie found value in its $9 billion Cerevel buy. A gene therapy dataset quietly shook one of biotech’s oldest promises. The gap between strategic and public capital is not theory anymore. It decides who survives and who disappears.
For Summit, AstraZeneca’s money is a lifeline. The deal also opens doors to AstraZeneca’s ADC pipeline and, through a second partnership, Daiichi Sankyo’s TROP2 ADC. The setup is unusual. Both AstraZeneca and Daiichi Sankyo are funding trials with Summit. Sam Fazeli calls it “a novel thing that I’ve not seen very often.” Instead of a standard licensing contract, they used a “memorandum of understanding.” That signals interest, not full commitment. Fazeli is blunt: “You can’t argue with $2 billion in the bank and a partner called AstraZeneca.” But the market is waiting. The real test is the Harmony 3 readout. No one agrees on when the data will come or what it will show. Schmidt expects PFS data late this year and OS data early next. He calls Harmony 3 “potentially the biggest binary event I’ve ever seen in the history of biotechnology.”
AstraZeneca’s investment was made at an implied price of $18.36 per common share, representing an 18.6% premium to Summit’s closing price on September 28, 2026. The announcement triggered a 23% surge in Summit’s shares during premarket trading, reflecting strong market enthusiasm for the partnership.
Blockbuster deals, but index gains mislead
Regeneron and Sanofi renewed their partnership around Dupixent, one of the world’s top-selling drugs. The new deal covers four antibodies on the same pathway. It includes $1 billion upfront, up to $7 billion in milestones, and 50-50 global profit-sharing. Still, buy-side skepticism remains. Fazeli points out that Sanofi’s CFO hinted at extending Dupixent’s patent protection “a few years beyond” 2031. Fazeli’s own analysis says protection could last until late 2037. The market barely reacted. Even blockbuster news struggles to move biotech stocks now.
Licensing deals are booming, especially in China. Novo Nordisk, Merck, and Novartis each signed major deals for obesity and oncology assets. Upfront payments ranged from $300 million to $575 million. At EASD in Milan, Lilly’s obesity pipeline took center stage. Regeneron showed MRI data for muscle preservation. But regulators have not accepted MRI as an endpoint yet. Mirum’s third FOP approval and AbbVie’s Juvemo nod for Parkinson’s disease prove battered assets can still deliver value. But only with the right strategic moves.
Clinical data, but market rewards are fickle
Not every clinical win pays off. Imix Biopharma posted an 89% complete response rate for its BCMA CAR-T in AL amyloidosis. That beats current standards by a wide margin. Yet its stock dropped nearly 10% after a $125 million follow-on financing “choked off” any rally. Kodiak Sciences, on the other hand, more than doubled on positive Phase 3 data for wet AMD. The difference? How the deal was financed and market mood, not the science. For context, a reported earlier BCMA CAR-T program in China hit a 95.9% response rate. Even world-class data can be ignored if the market is not ready to care.
Gene therapy got a reality check from UniQure’s four-year Huntington’s data. Efficacy faded from 75% to 44% slowing of disease progression. The stock fell 37% on the news. This happened even with a BLA submission and priority review request. Dyne Therapeutics’ DM1 program took a hit after Novartis failed in the same mechanism. But some still believe. Schmidt says Dyne has fixed many of the gaps left by others. If the registrational readout in 2027 is positive, “the stock’s going to rip.”
The split is clear. Strategic capital pays premiums and funds risky development. Public markets see only risk. AstraZeneca’s Summit deal, Moderna’s flat reaction to NASDAQ-100 inclusion, and Imix’s failed rally all show the same thing. Index gains hide a brutal two-tier market. Until the next wave of binary readouts—Harmony 3, Moderna’s RCC data, Amgen’s Delphi 305, Mirum’s hepatitis delta Phase 3, and Dyne’s DM1 cohort—this split will decide who wins and who loses. The lesson is simple. Headline numbers mean little if you do not know who is really holding the cards. Right now, strategic buyers are playing a different game than public investors.
